Background aims Decentralized, or distributed, manufacturing that takes place close to the
point of care has been a manufacturing paradigm of heightened interest within the cell …

Cell and gene therapies have demonstrated excellent clinical results across a range of
indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach …

Background aims Autologous cell therapy (AuCT) is an emerging therapeutic treatment that
is undergoing transformation from laboratory-to industry-scale manufacturing with recent …

Chimeric antigen receptor (CAR) T cells are considered a potentially disruptive cancer
therapy, showing highly promising results. Their recent success and regulatory approval …

The recent successes of adoptive T-cell immunotherapy for the treatment of hematologic
malignancies have highlighted the need for manufacturing processes that are robust and …

Abstract Chimeric Antigen Receptor (CAR) T cell therapies have received increasing
attention, showing promising results in the treatment of acute lymphoblastic leukaemia and …

As cell and gene therapies (CGT) assume center stage in early‐phase clinical trials for
several acute and chronic diseases, there is heightened interest in the standardization and …

A cost model was described using Biosolve to measure the impact of automation and
scaleout of a CAR-T manufacturing process, and associated supply chain. The partially …

Decentralized or “redistributed” manufacturing has the potential to revolutionize the
manufacturing approach for cell and gene therapies (CGTs), moving away from the “Fordist” …

Decentralized, or redistributed manufacture, is likely to be the manufacturing approach of
choice for some cell-and gene-based therapies, in particular, personalized therapies. Such …